Clinical Trials
10 trialsNCT02220985 2026-06-01
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT04681105 2026-01-28
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
Phase 1 Completed
NCT02113982 2024-08-01
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT02730312 2022-03-08
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Xencor, Inc.
Phase 1 Completed
NCT00014235 2020-01-21
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Phase NA Completed
NCT02652715 2019-11-15
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Phase NA Completed
NCT00397579 2019-04-23
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT02420873 2018-08-28
An Open-label Phase II Study of Lorvotuzumab Mertansine
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02859623 2016-08-09
LpDC
Centre Hospitalier Universitaire de Besancon
Completed
NCT01231919 2014-04-29
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
Phase 1 Completed